ClinicalTrials.gg
RecruitingNCT07495332Updated Apr 3, 2026

Siemens Biomarker Multi-modality

An interventional study of Photon-counting CT (PCCT) and Ultrasound in Fatty Liver and Hepatic Steatosis, sponsored by Duke University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-03.

Sponsored by Duke University · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 212 studies in Fatty Liver with a site in United States — 42 open to participants now, 48 under way, 8 of them phase 3. Fatty Liver · United States.

Planned enrollment
80th of 163
45 · median 44
Started
2026
with 14 others
No phase
61 of 212
10 open now
Primary completion
2027-05
later than 15 of 47 live
Registered
201st of 212
by date

Among the 212 studies in Fatty Liver with a site in United States, this one is the 80th largest by planned enrollment of the 163 interventional ones that give a count, is one of 15 that started in 2026, is one of 61 with no phase, reaches primary completion later than 15 of the 47 other live ones, and was the 201st registered.

Fatty Liver

666 studies on the registry are indexed under Fatty Liver; 188 are open to participants now.

Browse Fatty Liver studies →

Open to participants now

42 of the 212 studies in Fatty Liver with a site in United States are open now. Recruiting first, the newest first:

36 more — sign in →

All 42 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 118 Fatty Liver studies recruiting now, 36 (31%) set no upper age limit and 63 (53%) stop at 75 or younger; 8 take children under 18; 32 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 212 studies in Fatty Liver with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to see how well Photon Counting CT (PCCT) and ultrasound test results can find fat and scarring in the liver. They will be compared to MRI test results as the reference standard. Participants will get a regular CT scan on the PCCT scanner, plus a few extra pictures just for the study. They will also get an MRI, either on the same day or a different day, whichever is preferred. Participants will get an ultrasound on the same day as the MRI. If they have not had a hematocrit blood test in the past 24 hours, they will also receive one on the day of the CT scan.

03

Conditions studied

  • Fatty Liver
  • Hepatic Steatosis

Keywords

  • Fatty Liver
  • Liver Fibrosis
  • Hepatic steatosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age of 18 years or older
  • Has clinically indicated CT schedule including the liver (with contrast or with and without contrast)
  • Patient eligible for MR imaging
  • History of chronic diffuse liver disease, steatotic liver disease, and/ or liver fibrosis
  • Capable of consent

Exclusion criteria

Exclusion Criteria:

  • to any of the required imaging examinations
  • > 45 (based on MRI scanner capacity)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • Active comparator
    Photon Counting CT (PCCT)

    Participants will get a regular CT scan on the PCCT scanner, plus a few extra pictures just for the study.

    Diagnostic Test: Photon-counting CT (PCCT)

  • Active comparator
    MRI

    Participants will get an MRI, either on the same day as the PCCT scan or a different day, whichever is preferred.

    Diagnostic Test: Magnetic Resonance Imaging (MRI)

  • Active comparator
    Ultrasound

    Participants will get an ultrasound on the same day as the MRI.

    Diagnostic Test: Ultrasound

Interventions

  • Diagnostic testPhoton-counting CT (PCCT)

    Photon-counting computed tomography (PCCT) is a next-generation imaging technology using advanced detectors that directly count individual X-ray photons and measure their energy, rather than integrating total energy like traditional CT.

  • Diagnostic testUltrasound

    Ultrasound is a safe, radiation-free imaging technique using high-frequency sound waves to visualize soft tissues, organs, and blood flow in real-time.

  • Diagnostic testMagnetic Resonance Imaging (MRI)

    MRI is a noninvasive, radiation-free medical imaging technique that uses powerful magnets and radio waves to generate detailed, high-resolution 3D images of soft tissues, organs, and bones.

06

What researchers measure

Primary outcomes

  1. Sensitivity of CT-FF (computed tomography fat fraction)

    The percentage of patients with hepatic steatosis by MRI-PDFF who have positive CT-PDFF.

    Time frame: 1 day to 14 days

  2. Specificity of CT-FF (computed tomography fat fraction)

    The percentage of patients without hepatic steatosis by MRI-PDFF who have negative CT-PDFF.

    Time frame: 1 day to 14 days

Secondary outcomes

  1. Sensitivity of Ultrasound-Derived Fat Fraction (UDFF)

    The percentage of patients with hepatic steatosis by MRI-PDFF who have positive UDFF.

    Time frame: 1 day to 14 days

  2. Specificity of Ultrasound-Derived Fat Fraction (UDFF)

    The percentage of patients without hepatic steatosis by MRI-PDFF who have negative UDFF.

    Time frame: 1 day to 14 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for May 2027, 14 months after the start.

Of 136 non-industry interventional studies with no phase under Fatty Liver, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 14 months is below that.

Counting every sponsor, half of 145 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2026
First posted
Mar 27, 2026
StartActual
Mar 27, 2026
Primary completionEst.
May 2027
CompletionEst.
May 2027
Last update
Apr 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07495332
Lead sponsor
Duke University
Collaborators
Siemens Healthineers
Responsible party
Sponsor
First posted
Mar 27, 2026
Start date
Mar 27, 2026
Primary completion
May 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Apr 3, 2026

Study contacts

Mustafa Bashir, MD
Contact
mustafa.bashir@duke.edu
919-684-7366
Mustafa Bashir, MD
principal investigator · Duke University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion